Grifols SA
GRFS, GIFLF, GIFOF, GIKLY · Pharmaceutical Preparations · EDGAR filings ↗
Grade
B79gen composite 71pct→79
Notable findings
- Strong balance sheetStrong balance sheet — $1.0B cash & investments
- Notable holderHeld by 4 notable fund(s): GOLDMAN SACHS GROUP INC, STATE STREET CORP, FMR LLC +1 more (as of 2026-03-31)
Key metrics
Gross margin
38.7%
Operating margin
16.5%
Net margin
3.0%
Return on equity
2.5%
Return on assets
1.0%
ROIC
10.9%
Revenue growth (QoQ)
2.4%
Net-income growth
21.7%
Interest coverage
1.7×
Current ratio
2.7×
Free cash flow
$693M
EBITDA
$1.7B
Tangible book value
-$1.8B
Cash & investments
$1.0B
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-04-17 | 2025-12-31 | 0001104659-26-044901 ↗ |
| 20-F | 2025-04-11 | 2024-12-31 | 0001104659-25-034245 ↗ |
| 20-F | 2024-04-19 | 2023-12-31 | 0001104659-24-049471 ↗ |
| 20-F | 2023-04-18 | 2022-12-31 | 0001104659-23-046470 ↗ |
| 20-F | 2022-04-29 | 2021-12-31 | 0001104659-22-053197 ↗ |
| 20-F | 2021-04-09 | 2020-12-31 | 0001104659-21-048385 ↗ |
| 20-F | 2020-04-06 | 2019-12-31 | 0001104659-20-043470 ↗ |
| 20-F | 2019-04-05 | 2018-12-31 | 0001104659-19-020063 ↗ |
| 20-F | 2018-04-06 | 2017-12-31 | 0001104659-18-022787 ↗ |
| 20-F | 2017-04-04 | 2016-12-31 | 0001104659-17-021206 ↗ |
| 20-F | 2016-04-05 | 2015-12-31 | 0001104659-16-109722 ↗ |
| 20-F | 2015-04-01 | 2014-12-31 | 0001104659-15-024797 ↗ |